Stephens Downgrades Exact Sciences (EXAS) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Cuts Price Target on Exact Sciences (EXAS) Following Disappointing Outlook
February 25, 2016 9:29 AM ESTJefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
Roth Capital Downgrades Exact Sciences (EXAS) to Neutral
February 25, 2016 6:56 AM ESTRoth Capital downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $5.87 yesterday.
... MoreCraig-Hallum Downgrades Exact Sciences (EXAS) to Hold
February 24, 2016 1:37 PM ESTCraig-Hallum downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $6.41 yesterday.
... MoreExact Sciences (EXAS) Tops Q4 EPS by 6c, Maintains Cologuard Outlook
February 24, 2016 7:31 AM ESTExact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.41), $0.06 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $14.82 million.
2016 Outlook
The company continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating between... More
